1 / 21

JR Skillings Genentech, Inc, South San Francisco, CA

ARTERIAL THROMBOEMBOLIC EVENTS IN A POOLED ANALYSIS OF 5 RANDOMIZED, CONTROLLED TRIALS OF BEVACIZUMAB WITH CHEMOTHERAPY. JR Skillings Genentech, Inc, South San Francisco, CA. BACKGROUND.

uriel-petty
Download Presentation

JR Skillings Genentech, Inc, South San Francisco, CA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ARTERIAL THROMBOEMBOLIC EVENTS IN A POOLED ANALYSIS OF 5 RANDOMIZED, CONTROLLED TRIALS OF BEVACIZUMAB WITH CHEMOTHERAPY JR Skillings Genentech, Inc, South San Francisco, CA

  2. BACKGROUND • Bevacizumab (BV; AvastinTM) is a recombinant, humanized, anti-vascular endothelial growth factor (VEGF) monoclonal antibody • BV combined with first-line irinotecan, 5-fluorouracil (5-FU), and leucovorin (IFL) chemotherapy increases survival in patients with metastatic colorectal cancer (mCRC) • Safety reports from several randomized, controlled trials suggested that adding BV to chemotherapy may increase the risk of arterial thromboembolic events (ATEs)

  3. OBJECTIVE • To evaluate the risk of ATEs in patients with metastatic cancer receiving BV with chemotherapy using data pooled from 5 randomized, controlled trials

  4. METHODS: STUDY DESIGN CAP=capecitabine; C=carboplatin; P=paclitaxel MBC= metastatic breast cancer; NSCLC=non-small-cell lung cancer 1Hurwitz H, et al. N Engl J Med. 2004;350:2335-2342; 2Kabbinavar F, et al. J Clin Oncol. 2005. In Press; 3Kabbinavar F, et al. J Clin Oncol. 2003;21:60-65; 4Miller K, et al. J Clin Oncol. 2005; 23:792-799; 5Johnson D, et al. J Clin Oncol. 2004;22:2184-2191

  5. METHODS: IDENTIFICATION OF ATE CASES • The pooled database was broadly queried for adverse event terms that might be associated with the clinical consequences of ATEs • The following COSTART terms were used for the initial search: cerebrovascular accident, cerebral ischemia, subarachnoid hemorrhage, cerebral infarction, angina pectoris, myocardial infarction, myocardial ischemia, and arterial thrombosis. Thrombosis and verbatim terms including left ventricle were added • Death due to causes other than progressive disease were clinically reviewed for text fields including cerebrovascular accident, myocardial infarction or ATE. A case of ischemic bowel was added • The safety database was reviewed using broad search criteria and one additional case of right leg arterial occlusion was added • Cases of subarachnoid hemorrhage were removed because these were interpreted as bleeding events • Cases of cardiac arrest were removed when review of narratives suggested that the cases were related to progressive disease • A combined list of cases was identified

  6. METHODS: IDENTIFIED TREATMENT-EMERGENT ATEs

  7. METHODS: STATISTICAL ANALYSIS • Incidence of ATEs was tabulated for each treatment group • Kaplan-Meier plots of time-to-ATE were generated for each treatment group and median values estimated. A Cox proportional hazards regression was used to calculate hazard ratios, and P-values were calculated by the log-rank test • ATE rates per 100 person-years with 95% confidence intervals were computed by standard methods. The number of person-years of observation was defined as the sum of the time-to-ATE for all patients (for patients without an ATE, the observation time was defined as the last date of treatment plus 30 days) • Poisson regression was used to formally compare rates per 100 person-years between BV-treated patients and controls

  8. METHODS: BASELINE VARIABLES USED FOR POTENTIAL RISK FACTOR ANALYSIS DBP=diastolic blood pressure; HTN=hypertension; SBP=systolic blood pressure

  9. METHODS: OTHER BASELINE VARIABLES USED FOR POTENTIAL RISK FACTOR ANALYSIS TIA=transient ischemic attack

  10. METHODS: POTENTIAL RISK FACTOR ANALYSIS • For each risk factor, numbers of patients with and without the factor were tabulated • Fisher’s exact test was used to compare the frequency of ATEs between BV-treated and control patients for each risk factor • Cox’s proportional hazards regression was used to compute hazard ratios and P-values for the effect of each factor on the hazard of ATEs • Backward elimination in a multivariate Cox model was used to assess the significance of each baseline risk factor that was significant in univariate analysis • Pooled population patients were assigned to subgroups based on significant baseline risk factors, and ATE rates per 100 person-years were calculated as described above within each subgroup by treatment • Irinotecan-treated patients from the pivotal trial in mCRC (AVF2107g)1 were assigned to subgroups based on these risk factors. Median PFS and overall survival were estimated for each subgroup using Kaplan-Meier methods, and hazard ratios were calculated from a Cox proportional hazards model 1Hurwitz H, et al. N Engl J Med. 2004;350:2335-2342

  11. RESULTS: INCIDENCE OF ATEs FOR EACH TREATMENT GROUP MBC= metastatic breast cancer; NSCLC=non-small-cell lung cancer 1Hurwitz H, et al. N Engl J Med. 2004;350:2335-2342; 2Kabbinavar F, et al. J Clin Oncol. 2005. In Press; 3Kabbinavar F, et al. J Clin Oncol. 2003;21:60-65; 4Miller K, et al. J Clin Oncol. 2005; 23:792-799; 5Johnson D, et al. J Clin Oncol. 2004;22:2184-2191

  12. RESULTS: ATE ANALYSIS CI=confidence interval *P=0.076; **P=0.03

  13. RESULTS: KAPLAN-MEIER TIME-TO-ATE Patientsat risk by time point 0 5 10 15 20 25 Months 782 405 173 64 17 0 control 963683 421 260 111 15 chemo/AVF Uncorrected for uneven time on treatment and shorter follow up for control patients

  14. RESULTS: ATE POTENTIAL RISK FACTORS IN UNIVARIANT ANALYSIS DBP=diastolic blood pressure; HTN=hypertension; SBP=systolic blood pressure *On study indicates occurrence during treatment (and prior to an ATE if one occurred) †Collected in selected trials1-3 1Hurwitz H, et al. N Engl J Med. 2004;350:2335-2342; 2Kabbinavar F, et al. J Clin Oncol. 2005. In Press; 3Miller K, et al. J Clin Oncol. 2005; 23:792-799

  15. RESULTS: RELATIONSHIP BETWEEN ATEs AND PROTEINURIA • Patients with proteinuria (>500mg/24 hours) are at risk of ATEs regardless of treatment. The explanation for this finding is unclear Proteinuria (>500mg/24 hours) n=subset; N=total number

  16. RESULTS: BASELINE ATE RISK FACTORS SIGNIFICANT IN MULTIVARIATE ANALYSIS • In a multivariate analysis with both baseline and on-study factors, no on-study factors were significant except presence of proteinuria >500mg/24 hours • In a separate multivariate analysis with only on-study factors, presence of proteinuria alone was significant

  17. RESULTS: RISK/BENEFIT OF BV in mCRC • To understand the risk/benefit of BV in mCRC, data from the pivotal trial AVF21071 were reanalyzed* for survival based on subgroups created using risk factors for ATEs *The dataset used to support the preplanned final analysis for AVF2107g was used for this analysis 1Hurwitz H, et al. N Engl J Med. 2004;350:2335-2342

  18. RESULTS: ATE INCIDENCE BY RISK GROUP n=subgroup; N=total number *These groups are not mutually exclusive

  19. RESULTS: SURVIVAL HAZARD RATIOS IN mCRC BY RISK GROUP CI=confidence interval; PFS=progression-free survival *These groups are not mutually exclusive 1Hurwitz H, et al. N Engl J Med. 2004;350:2335-2342

  20. CONCLUSIONS • Bevacizumab is associated with an approximately 2-fold increased risk of ATEs in patients with metastatic cancer receiving chemotherapy • Age ≥65 years and a history of ATEs are independent baseline risk factors for these events

  21. CONCLUSIONS (cont’d) • Despite this risk, analysis of data from the pivotal trial1 indicate that bevacizumab confers a consistent survival benefit in mCRC patients overall, in all prespecified subgroups, and in these ATE risk subgroups • Oncologists must use their own clinical judgment in assessing the overall risk/benefit of adding bevacizumab to chemotherapy in patients at risk of ATEs 1Hurwitz H, et al. N Engl J Med. 2004;350:2335-2342

More Related